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Breast cancer is one of the most common cancers among
women. The risk of breast cancer has increased dramati-
cally recently and a higher number of elderly women are
being diagnosed with the disease. Myeloid-derived
suppressor cells (MDSCs) have been implicated in breast
cancer prognosis. Their frequency has been associated
with tumour burden and studies have shown a poor prog-
nosis in cases of metastatic breast cancer. MDSCs are
known to impair the proliferation of T cells and to
promote T cell apoptosis. Associations between MDSC
levels and immune responses of the host to tumour-
associated antigens had not been investigated. Here, we
have studied T cell responses to Her-2 antigens, as well as
the frequency of Tregs and MDSCs, in 40 untreated breast
cancer patients (65-87 years of age) at diagnosis. After a
12-day in vitro expansion of memory cells stimulated by
Her-2-derived peptides, CD4+ T cells reactive to Her-2
were detected in 84% of patients by intracytoplasmic stain-
ing simultaneously for TNF, IFN-g, IL-2, IL-5, IL-10 and
IL-17. In contrast, only 47% of patients had Her-2-reactive
CD8+ T cells. The patients who lacked a CD8 response
tended to have higher frequencies of Lineage(neg) CD14+
HLA-DR(neg) cells (p = 0.09). Importantly, the 5-year
survival rate of patients who mounted a CD8+ T cell
response and had a lower frequency of this particular sub-
set of MDSC was 100% compared to only 53% in patients
without Her-2-reactive CD8+ T cells and with higher fre-
quencies of MDSCs (p = 0.03). This survival advantage
was also observed in non-metastatic patients, with only a
38% 5-year survival in patients without a CD8 response
and high levels of MDSCs compared to 100% survival of
those who had a CD8 response and a lower frequency of
MDSCs (p = 0.016). Similarly, for Tregs, patients who
lacked a CD8 response to Her-2 and had higher frequen-
cies of CD4+ Foxp3+ CD127(low) CD25+ Tregs had only
50% survival when compared to the 100% survival of the
patients who mounted a CD8 response and had lower
frequency of Tregs (p = 0.03). Also, for activated CD4+
CD45RA(neg)Foxp3(hi) Tregs, a similar trend was
observed with 57% survival in patients who lacked a CD8
response and had higher frequencies of activated Tregs
compared to the 100% survival in patients with a CD8
response and lower frequencies of activated Tregs
(p = 0.06). Our data thus demonstrate a negative role of
MDSCs and Tregs in prognosis of breast cancer patients,
which might be through dampening favorable immune
responses to tumour-associated antigens.
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